Phase 2 Chronic Low Back Pain Study
A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects With Chronic Low Back Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Site Reference ID/Investigator# 54875
-
-
California
-
Anaheim, California, United States, 92801
- Site Reference ID/Investigator# 54876
-
Burbank, California, United States, 91505
- Site Reference ID/Investigator# 54877
-
Lomita, California, United States, 90717
- Site Reference ID/Investigator# 54873
-
-
Florida
-
DeLand, Florida, United States, 32720
- Site Reference ID/Investigator# 54874
-
Oldsmar, Florida, United States, 34677
- Site Reference ID/Investigator# 54866
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Site Reference ID/Investigator# 54879
-
-
Indiana
-
Valparaiso, Indiana, United States, 46383
- Site Reference ID/Investigator# 54865
-
-
Kansas
-
Prairie Village, Kansas, United States, 66206
- Site Reference ID/Investigator# 54782
-
-
Maryland
-
Pasadena, Maryland, United States, 21122
- Site Reference ID/Investigator# 54862
-
-
Massachusetts
-
Watertown, Massachusetts, United States, 02472-3930
- Site Reference ID/Investigator# 54878
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- Site Reference ID/Investigator# 54880
-
-
New York
-
Williamsville, New York, United States, 14221
- Site Reference ID/Investigator# 54881
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Site Reference ID/Investigator# 54872
-
Marion, Ohio, United States, 43302
- Site Reference ID/Investigator# 54863
-
-
Texas
-
Killeen, Texas, United States, 76543
- Site Reference ID/Investigator# 54745
-
San Antonio, Texas, United States, 78209-1744
- Site Reference ID/Investigator# 54742
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adult subjects who have a diagnosis of chronic low back pain of at least 6 month duration
Exclusion Criteria:
Subjects with a history of surgical or invasive intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Open-label Hydrocodone/Acetaminophen Extended Release
Hydrocodone/acetaminophen extended release, 2 tablets twice daily
|
Other Names:
|
|
Experimental: Double-blind Hydrocodone/Acetaminophen Extended Release
Hydrocodone/acetaminophen extended release, 1 tablet twice daily
|
Other Names:
|
|
Placebo Comparator: Double-blind Placebo
Placebo, 1 tablet twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Double-blind Baseline in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)
Time Frame: Double-blind baseline to Day 29
|
The change from the double-blind randomization baseline (DB baseline: the last assessment before first dose in the double-blind period) to the final assessment in pain intensity, assessed using the CLBP Intensity VAS (0 mm = No Pain and 100 mm = Worst Pain Imaginable).
Least squares means and standard errors from an ANCOVA model.
|
Double-blind baseline to Day 29
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant's Global Assessment of Back Pain Status at Final Evaluation
Time Frame: Double-blind baseline to Day 29
|
The participant's overall impression of their back pain status was obtained by having the participant answer the question "Considering all the ways your chronic low back pain affects you, how are you doing today?" on a 5-point categorical scale: very good (no symptoms and no limitation of normal activities); good (mild symptoms and no limitation of normal activities); fair (moderate symptoms and limitation of some normal activities); poor (severe symptoms and inability to carry out most normal activities); very poor (very severe symptoms which are intolerable and inability to carry out all normal activities).
|
Double-blind baseline to Day 29
|
|
Participant's Global Assessment of Study Drug at Final Evaluation
Time Frame: Double-blind baseline to Day 29
|
The participant's overall impression of the study drug was obtained by having the participant answer the question "How would you rate your overall response to the study medication?" on a 5-point categorical scale: excellent; very good; good; fair; poor.
|
Double-blind baseline to Day 29
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Back Pain
- Low Back Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antipyretics
- Analgesics, Opioid
- Narcotics
- Respiratory System Agents
- Antitussive Agents
- Acetaminophen
- Hydrocodone
- Acetaminophen, hydrocodone drug combination
Other Study ID Numbers
Other Study ID Numbers
- M12-807
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.